


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

ELIGIBILITY

CONCURRENT COMPONENTS OF VISIT

DISPOSITION



NED = no evidence of disease

<sup>1</sup> Consider use of Vanderbilt’s [ABCDE’s approach to cardiovascular health](#)

<sup>2</sup> Based on [Centers for Disease Control and Prevention \(CDC\) guidelines](#)

<sup>3</sup> See [Physical Activity](#), [Nutrition](#), and [Tobacco Cessation](#) algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

<sup>4</sup> Includes [breast](#), [cervical](#) (if appropriate), [colorectal](#), [liver](#), [lung](#), [pancreatic](#), [prostate](#), and [skin cancer screening](#)

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

---

## SUGGESTED READINGS

- Arden-Close, E., Pacey, A., & Eiser, C. (2010). Health-related quality of life in survivors of lymphoma: A systematic review and methodological critique. *Leukemia & Lymphoma*, 51(4), 628-640. doi:10.3109/10428191003587263
- Asia Pacific Immunoglobulins in Immunology Expert Group Inc. (APIEG). (2009). *Consensus Recommendations for the Use of Immunoglobulin Replacement Therapy in Immune Deficiency* (2nd ed.). Retrieved from <http://www.apiieg.org/files/1/APIIEG%20Consensus%20Recommendations%20Edition%201%20June%202008.pdf>
- Bari, A., Marcheselli, L., Marcheselli, R., Liardo, E. V., Pozzi, S., Ferri, P., & Sacchi, S. (2011). Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. *Mediterranean Journal of Hematology & Infectious Diseases*, 3(1), e2011065. doi:10.484/MJHID.2011.065
- Beckjord, E. B., Arora, N. K., Bellizzi, K., Hamilton, A. S., & Rowland, J. H. (2011, September). Sexual well-being among survivors of non-Hodgkin lymphoma. *Oncology Nursing Forum* 38(5), E351-E359. doi:10.1188/11.ONF.E351-E359
- Bellizzi, K. M., Rowland, J. H., Arora, N. K., Hamilton, A. S., Miller, M. F., & Aziz, N. M. (2009). Physical activity and quality of life in adult survivors of non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, 27(6), 960-966. doi:10.1200/JCO.2008.17.5026
- Centers for Disease Control and Prevention. (2018). *Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018*. Retrieved from <https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>
- Hess, S. L., Jóhannsdóttir, I. M., Hamre, H., Kiserud, C. E., Loge, J. H., & Fosså, S. D. (2011). Adult survivors of childhood malignant lymphoma are not aware of their risk of late effects. *Acta Oncologica*, 50(5), 653-659. doi:10.3109/0284186x.2010.550934
- Knezevic-Maramica, I., Kruskall, M. (2003). Intravenous immune globulins: An update for clinicians. *Transfusion*, 43(10), 1460-1480. doi:10.1046/j.1537-2995.2003.00519.x
- Link, B. K., Martin, P., Kaminski, M. S., Goldsmith, S. J., Coleman, M., & Leonard, J. P. (2010). Cyclophosphamide, vincristine, and prednisone followed by tositumomab and Iodine- 131–tositumomab in patients with untreated low-grade follicular lymphoma: Eight-year follow-up of a multicenter phase II study. *Journal of Clinical Oncology*, 28(18), 3035-3041. doi:10.1200/JCO.2009.27.8325
- McNamara, C., Davies, J., Dyer, M., Hoskin, P., Illidge, T., Lyttelton, M., ... Ardeshtna, K. (2012). Guidelines on the investigation and management of follicular lymphoma. *British Journal of Haematology*, 156(4), 446-467. doi:10.1111/j.1365-2141.2011.08969.x
- Mols, F., Aaronson, N. K., Vingerhoets, A. J., Coebergh, J. W., Vreugdenhil, G., Lybeert, M. L., & van de Poll-Franse, L. V. (2007). Quality of life among long-term non-Hodgkin lymphoma survivors. *Cancer*, 109(8), 1659-1667. doi:10.1002/cncr.22581
- Morton, L. M., Curtis, R. E., Linet, M. S., Bluhm, E. C., Tucker, M. A., Caporaso, N., ... Fraumeni, J. F. (2010). Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: Differences by lymphoma subtype. *Journal of Clinical Oncology*, 28(33), 4935-4944. doi:10.1200/JCO.2010.29.1112

*Continued on Next Page*

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

---

## SUGGESTED READINGS - continued

- Pirani, M., Marcheselli, R., Marcheselli, L., Bari, A., Federico, M., & Sacchi, S. (2011). Risk for second malignancies in non-Hodgkin's lymphoma survivors: A meta-analysis. *Annals of Oncology*, 22(8), 1845-1858. doi:10.1093/annonc/mdq697
- Sacchi, S., Marcheselli, L., Bari, A., Marcheselli, R., Pozzi, S., Luminari, S., ... Brugiattelli, M. (2008). Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study. *Haematologica*, 93(3), 398-404. doi:10.3324/haematol.12120
- Seymour, J. F., Pro, B., Fuller, L. M., Manning, J. T., Hagemester, F. B., Romaguera, J., ... McLaughlin, P. (2003). Long-term follow-up of a prospective study of combined modality therapy for stage I–II indolent non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, 21(11), 2115-2122. doi:10.1200/JCO.2003.07.111
- Shenoy, P., Sinha, R., Tume, J. W., Lechowicz, M. J., & Flowers, C. R. (2010). Surveillance computed tomography scans for patients with lymphoma: Is the risk worth the benefits? *Clinical Lymphoma Myeloma and Leukemia*, 10(4), 270-277. doi:10.3816/CLML.2010.n.056
- Smith, S. K., Crespi, C. M., Petersen, L., Zimmerman, S., & Ganz, P. A. (2010). The impact of cancer and quality of life for post-treatment non-Hodgkin lymphoma survivors. *Psycho-Oncology*, 19(12), 1259-1267. doi:10.1002/pon.1684
- Smith, S. K., Williams, C. S., Zimmer, C. R., & Zimmerman, S. (2010). An exploratory model of the relationships between cancer-related trauma outcomes on quality of life in non-Hodgkin lymphoma survivors. *Journal of Psychosocial Oncology*, 29(1), 19-34. doi:10.1080/07347332.2011.534022
- Smith, S. K., Zimmerman, S., Williams, C. S., Benecha, H., Abernethy, A. P., Mayer, D. K., ... Ganz, P. A. (2011). Post-traumatic stress symptoms in long-term non-Hodgkin's lymphoma survivors: does time heal? *Journal of Clinical Oncology*, 29(34), 4526-4533. doi:10.1200/JCO.2011.37.2631
- Smith, S. K., Zimmerman, S., Williams, C. S., & Zebrack, B. J. (2009). Health status and quality of life among non-Hodgkin lymphoma survivors. *Cancer*, 115(14), 3312-3323. doi:10.1002/cncr.24391
- Vanderbilt Cardio-Oncology Program. (2017). *Know Your ABCDE's*. Retrieved from <http://www.cardioonc.org/2017/08/29/know-your-abcs/>
- Wilder, R. B., Jones, D., Tucker, S. L., Fuller, L. M., Ha, C. S., McLaughlin, P., ... Cox, J. D. (2001). Long-term results with radiotherapy for stage I–II follicular lymphomas. *International Journal of Radiation Oncology\* Biology\* Physics*, 51(5), 1219-1227. doi:10.1016/S0360-3016(01)01747-3

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.*

## DEVELOPMENT CREDITS

This survivorship algorithm is based on majority expert opinion of the Lymphoma Survivorship work group at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

- Luis E. Fayad, MD (Lymphoma/Myeloma)
- Olga N. Fleckenstein♦
- Nathan Fowler, MD (Lymphoma/Myeloma)
- Fredrick Hagemeister, MD (Lymphoma/Myeloma)
- Thoa Kazantsev, BSN, RN, OCN♦
- Hun Lee, MD (Lymphoma/Myeloma)
- Paula Lewis-Patterson, DNP, RN, NEA-BC (Cancer Survivorship)
- Loretta Nastoupil, MD (Lymphoma/Myeloma)
- Sattva Neelapu, MD (Lymphoma/Myeloma)
- Amy Pai, PharmD♦
- Alma Rodriguez, MD (Lymphoma/Myeloma)
- Felipe Samaniego, MD (Lymphoma/Myeloma)<sup>†</sup>
- Jason Westin, MD (Lymphoma/Myeloma)

<sup>†</sup> Core Development Lead  
♦ Clinical Effectiveness Development Team